Left Ventricular Physiology and Pathophysiology in Hypertension

Comprehensive Hypertension

Volumn , Issue , 2007, Pages 113-121

  Booz, George W ^a,b,c  

^a TEXAS A AND M UNIVERSITY SYSTEM   (United States)

^b SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^c Cardiovascular Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882903964     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-03961-1.50013-1     Document Type: Chapter

References (78)

1. D Levy, RJ Garrison, DD Savage, WB Kannel and WP Castelli (1990) Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322 1561-1566.
2. MJ Koren, RB Devereux, PN Casale, DD Savage and JH Laragh (1991) Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 114 345-352.
3. G de Simone, V Palmieri, MJ Koren, GA Mensah, MJ Roman and RB Devereux (2001) Prognostic implications of the compensatory nature of left ventricular mass in arterial hypertension. J Hypertens 19 119-125.
4. V Palmieri, K Wachtell, E Gerdts, JN Bella, V Papademetriou, C Tuxen, et al. (2001) Left ventricular function and hemodynamic features of inappropriate left ventricular hypertrophy in patients with systemic hypertension: the LIFE study. Am Heart J 141 784-791.
5. V Palmieri, K Wachtell, JN Bella, E Gerdts, V Papademetriou, MS Nieminen, et al. (2004) Usefulness of the assessment of the appropriateness of left ventricular mass to detect left ventricular systolic and diastolic abnormalities in absence of echocardiographic left ventricular hypertrophy: the LIFE study. J Hum Hypertens 18 423-430.
6. G de Simone, P Verdecchia, S Pede, M Gorini and AP Maggioni (2002) Prognosis of inappropriate left ventricular mass in hypertension: the MAVI study. Hypertension 40 470-476.
7. G de Simone, DW Kitzman, V Palmieri, JE Liu, A Oberman, PN Hopkins, JN Bella, DC Rao, DK Arnett and RB Devereux (2004) Association of inappropriate left ventricular mass with systolic and diastolic dysfunction: the HyperGEN study. Am J Hypertens 17 828-833.
8. G Selvetella, E Hirsch, A Notte, G Tarone and G Lembo (2004) Adaptive and maladaptive hypertrophic pathways: points of convergence and divergence. Cardiovasc Res 63 373-380.
9. RB Devereux and MJ Roman (1999) Left ventricular hypertrophy in hypertension: stimuli, patterns, and consequences. Hypertens Res 22 1-9.
10. JJ Hunter and KR Chien (1999) Signaling pathways for cardiac hypertrophy and failure. N Engl J Med 341(17), 1276-1283.
11. N Reichek (1992) Patterns of left ventricular response in essential hypertension. J Am Coll Cardiol 19 1559-1560.
12. A Ganau, RB Devereux, MJ Roman, G de Simone, TG Pickering, PS Saba, et al. (1992) Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol 19 1550-1558.
13. P Verdecchia, G Schillaci, C Borgioni, A Ciucci, M Battistelli, C Bartoccini, et al. (1995) Adverse prognostic significance of concentric remodeling of the left ventricle in hypertensive patients with normal left ventricular mass. J Am Coll Cardiol 25 871-878.
14. A Gonzalez, B Lopez and J Diez (2004) Fibrosis in hypertensive heart disease: role of the renin-angiotensin-aldosterone system. Med Clin North Am 88 83-97.
15. VJ Dzau (1993) The role of mechanical and humoral factors in growth regulation of vascular smooth muscle and cardiac myocytes. Curr Opin Nephrol Hypertens 2 27-32.
16. MA Hefti, BA Harder, HM Eppenberger and MC Schaub (1997) Signaling pathways in cardiac myocyte hypertrophy. J Mol Cell Cardiol 29 2873-2892.
17. KD Schluter and HM Piper (1999) Regulation of growth in the adult cardiomyocytes. FASEB J (Suppl 13), S17-S22.
18. KR Chien, H Zhu, KU Knowlton, W Miller-Hance, M van-Bilsen, TX O'Brien, et al. (1993) Transcriptional regulation during cardiac growth and development. Annu Rev Physiol 55 77-95.
19. JJ Lehman and DP Kelly (2002) Gene regulatory mechanisms governing energy metabolism during cardiac hypertrophic growth. Heart Fail Rev 7 175-185.
20. HS Leong, RW Brownsey, JE Kulpa and MF Allard (2003) Glycolysis and pyruvate oxidation in cardiac hypertrophy—why so unbalanced? Comp Biochem Physiol A Mol Integr Physiol 135 499-513.
21. B Lopez, A Gonzalez, N Varo, C Laviades, R Querejeta and J Diez (2001) Biochemical assessment of myocardial fibrosis in hypertensive heart disease. Hypertension 38 1222-1226.
22. JS Janicki, GL Brower, JD Gardner, AL Chancey and JA Stewart Jr (2004) The dynamic interaction between matrix metalloproteinase activity and adverse myocardial remodeling. Heart Fail Rev 9 33-42.
23. S Hein, E Arnon, S Kostin, M Schonburg, A Elsasser, V Polyakova, et al. (2003) Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation 107 984-991.
24. WS Post, MG Larson, RH Myers, M Galderisi and D Levy (1997) Heritability of left ventricular mass: the Framingham Heart Study. Hypertension 30 1025-1028.
25. H Schunkert and J Erdmann (2003) Well kept secrets of the genome. Eur Heart J 24 501-503.
26. GS Bleumink, AF Schut, MC Sturkenboom, JW Deckers, CM van Duijn and BH Stricker (2004) Genetic polymorphisms and heart failure. Genet Med 6(6), 465-474.
27. T Kuznetsova, JA Staessen, A Olszanecka, A Ryabikov, K Stolarz, S Malyutina, et al. (2003) Maternal and paternal influences on left ventricular mass of offspring. Hypertension 41 69-74.
28. JN Bella, JW MacCluer, MJ Roman, L Almasy, KE North, LG Best, et al. (2004) Heritability of left ventricular dimensions and mass in American Indians: the Strong Heart Study. J Hypertens 22 281-286.
29. DK Arnett, Y Hong, JN Bella, A Oberman, DW Kitzman, PN Hopkins, et al. (2001) Sibling correlation of left ventricular mass and geometry in hypertensive African Americans and whites: the HyperGEN study. Hypertension Genetic Epidemiology Network. Am J Hypertens 14 1226-1230.
30. L Swan, DH Birnie, S Padmanabhan, G Inglis, JM Connell and WS Hillis (2003) The genetic determination of left ventricular mass in healthy adults. Eur Heart J 24 577-582.
31. H Schunkert, U Brockel, C Hengstenberg, A Luchner, MW Muscholl, K Kurzidim, et al. (1999) Familial predisposition of left ventricular hypertrophy. J Am Coll Cardiol 33 1685-1691.
32. TD Adams, FG Yanowitz, AG Fisher, JD Ridges, AG Nelson, AD Hagan, et al. (1985) Heritability of cardiac size: an echocardiographic and electrocardiographic study of monozygotic and dizygotic twins. Circulation 71 39-44.
33. GA Harshfield, CE Grim, C Hwang, DD Savage and SJ Anderson (1990) Genetic and environmental influences on echocardiographically determined left ventricular mass in black twins. Am J Hypertens 3 538-543.
34. HA Verhaaren, RM Schieken, M Mosteller, JK Hewitt, LJ Eaves and WE Nance (1991) Bivariate genetic analysis of left ventricular mass and weight in pubertal twins (the Medical College of Virginia twin study). Am J Cardiol 68 661-668.
35. AV Chobanian, GL Bakris, HR Black, WC Cushman, LA Green, JL Izzo Jr, et al. (2003) Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 1206-1252.
36. JR Kizer, DK Arnett, JN Bella, M Paranicas, DC Rao, MA Province, et al. (2004) Differences in left ventricular structure between black and white hypertensive adults: the Hypertension Genetic Epidemiology Network study. Hypertension 43 1182-1188.
37. R Lorber, SS Gidding, ML Daviglus, LA Colangelo, K Liu and JM Gardin (2003) Influence of systolic blood pressure and body mass index on left ventricular structure in healthy African-American and white young adults: the CARDIA study. J Am Coll Cardiol 41 955-960.
38. C Dekkers, FA Treiber, G Kapuku, EJ Van Den Oord and H Snieder (2002) Growth of left ventricular mass in African American and European American youth. Hypertension 39 943-951.
39. T Kuznetsova, JA Staessen, JG Wang, J Gasowski, Y Nikitin, A Ryabikov, et al. (2000) Antihypertensive treatment modulates the association between the D/I ACE gene polymorphism and left ventricular hypertrophy: a meta-analysis. J Hum Hypertens 14 447-454.
40. G Iaccarino, F Lanni, E Cipolletta, V Trimarco, R Izzo, GL Iovino, et al. (2004) The Glu27 allele of the β2 adrenergic receptor increases the risk of cardiac hypertrophy in hypertension. J Hypertens 22 2117-2122.
41. GS Bleumink, AF Schut, MC Sturkenboom, JA Janssen, JC Witteman, CM van Duijn, et al. (2005) A promoter polymorphism of the insulin-like growth factor-I gene is associated with left ventricular hypertrophy. Heart 91 239-240.
42. P Hallberg, L Lind, K Michaelsson, J Karlsson, L Kurland, T Kahan, et al. (2003) B2 bradykinin receptor (B2BKR) polymorphism and change in left ventricular mass in response to antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. J Hypertens 21 621-624.
43. U Liljedahl, T Kahan, K Malmqvist, H Melhus, AC Syvanen, L Lind, et al. (2004) Single nucleotide polymorphisms predict the change in left ventricular mass in response to antihypertensive treatment. J Hypertens 22 2321-2328.
44. L Kurland, H Melhus, J Karlsson, T Kahan, K Malmqvist, P Ohman, et al. (2002) Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. J Hypertens 20 657-663.
45. T Kuznetsova, JA Staessen, L Thijs, C Kunath, A Olszanecka, A Ryabikov, et al. (2004) Left ventricular mass in relation to genetic variation in angiotensin II receptors, renin system genes, and sodium excretion. Circulation 110 2644-2650.
46. P Stella, G Bigatti, L Tizzoni, C Barlassina, C Lanzani, G Bianchi, et al. (2004) Association between aldosterone synthase (CYP11B2) polymorphism and left ventricular mass in human essential hypertension. J Am Coll Cardiol 43 265-270.
47. P Segers, N Stergiopulos and N Westerhof (2000) Quantification of the contribution of cardiac and arterial remodeling to hypertension. Hypertension 36 760-765.
48. WC Cushman (2003) The burden of uncontrolled hypertension: morbidity and mortality associated with disease progression. J Clin Hypertens (Greenwich) 5(Suppl 2), 14-22.
49. JN Bella, MJ Roman, R Pini, JE Schwartz, TG Pickering and RB Devereux (1999) Assessment of arterial compliance by carotid midwall strain-stress relation in hypertension. Hypertension 33 793-799.
50. MJ Roman, TG Pickering, JE Schwartz, R Pini and RB Devereux (1996) Relation of arterial structure and function to left ventricular geometric patterns in hypertensive adults. J Am Coll Cardiol 28 751-756.
51. Y Shigematsu, M Hamada, M Mukai, H Matsuoka, T Sumimoto and K Hiwada (1995) Clinical evidence for an association between left ventricular geometric adaptation and extracardiac target organ damage in essential hypertension. J Hypertens 13 155-160.
52. J Blake, RB Devereux, EM Herrold, M Jason, J Fisher, JS Borer, et al. (1988) Relation of concentric left ventricular hypertrophy and extracardiac target organ damage to supranormal left ventricular performance in established essential hypertension. Am J Cardiol 62 246-252.
53. JK Ghali, Y Liao and RS Cooper (1998) Influence of left ventricular geometric patterns on prognosis in patients with or without coronary artery disease. J Am Coll Cardiol 31 1635-1640.
54. P Fesler, G Du Cailar, J Ribstein and A Mimran (2003) Left ventricular remodeling and renal function in never-treated essential hypertension. J Am Soc Nephrol 14 881-887.
55. JN Bella, K Wachtell, K Boman, V Palmieri, V Papademetriou, E Gerdts, et al. (2002) Relation of left ventricular geometry and function to aortic root dilatation in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study). Am J Cardiol 89 337-341.
56. GL Jennings (2004) The left atrium in hypertension: next to the chamber of power. J Hypertens 22 1473-1474.
57. E Gerdts, L Oikarinen, V Palmieri, JE Otterstad, K Wachtell, K Boman, et al. (2002) Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study. Hypertension 39 739-743.
58. RB Devereux, G de Simone, TG Pickering, JE Schwartz and MJ Roman (1998) Relation of left ventricular midwall function to cardiovascular risk factors and arterial structure and function. Hypertension 31 929-936.
59. P Palatini, P Visentin, P Mormino, M Pietra, D Piccolo, E Cozzutti, et al. (1998) Left ventricular performance in the early stages of systemic hypertension. HARVEST Study Group. Hypertension and Ambulatory Recording Venetia Study. Am J Cardiol 81 418-423.
60. K Wachtell, J Rokkedal, JN Bella, T Aalto, B Dahlof, G Smith, et al. (2001) Effect of electrocardiographic left ventricular hypertrophy on left ventricular systolic function in systemic hypertension (the LIFE study). Losartan Intervention for Endpoint. Am J Cardiol 87 54-60.
61. G Schillaci, G Vaudo, L Pasqualini, G Reboldi, C Porcellati and P Verdecchia (2002) Left ventricular mass and systolic dysfunction in essential hypertension. J Hum Hypertens 16 117-122.
62. P Palatini, P Visentin, P Mormino, L Mos, C Canali, F Dorigatti, et al. (1998) Structural abnormalities and not diastolic dysfunction are the earliest left ventricular changes in hypertension. HARVEST Study Group. Am J Hypertens 11 147-154.
63. G de Simone, R Greco, G Mureddu, C Romano, R Guida, A Celentano, et al. (2000) Relation of left ventricular diastolic properties to systolic function in arterial hypertension. Circulation 101 152-157.
64. AE Schussheim, JA Diamond, JS Jhang and RA Phillips (1998) Midwall fractional shortening is an independent predictor of left ventricular diastolic dysfunction in asymptomatic patients with systemic hypertension. Am J Cardiol 82 1056-1059.
65. K Wachtell, G Smith, E Gerdts, B Dahlof, MS Nieminen, V Papademetriou, et al. (2000) Left ventricular filling patterns in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study). Losartan Intervention for Endpoint. Am J Cardiol 85 466-472.
66. K Wachtell, V Papademetriou, G Smith, E Gerdts, B Dahlof, E Engblom, et al. (2004) Relation of impaired left ventricular filling to systolic midwall mechanics in hypertensive patients with normal left ventricular systolic chamber function: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study. Am Heart J 148 538-544.
67. V Palmieri, G de Simone, MJ Roman, JE Schwartz, TG Pickering and RB Devereux (1999) Ambulatory blood pressure and metabolic abnormalities in hypertensive subjects with inappropriately high left ventricular mass. Hypertension 34 1032-1040.
68. OO Akinboboye, RL Chou and SR Bergmann (2004) Myocardial blood flow and efficiency in concentric and eccentric left ventricular hypertrophy. Am J Hypertens 17 433-438.
69. S Schafer, M Kelm, S Mingers and BE Strauer (2002) Left ventricular remodeling impairs coronary flow reserve in hypertensive patients. J Hypertens 20 1431-1437.
70. ML Muiesan, M Salvetti, C Monteduro, B Bonzi, A Paini, S Viola, et al. (2004) Left ventricular concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive patients. Hypertension 43 731-738.
71. M Zabalgoitia, J Berning, MJ Koren, A Stoylen, MS Nieminen, B Dahlof, et al. (2001) Impact of coronary artery disease on left ventricular systolic function and geometry in hypertensive patients with left ventricular hypertrophy (the LIFE study). Am J Cardiol 88 646-650.
72. SA Hunt, DW Baker, MH Chin, MP Cinquegrani, AM Feldman, GS Francis, et al. (2001) ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure) developed in collaboration with the International Society for Heart and Lung Transplantation, endorsed by the Heart Failure Society of America. Circulation 104 2996-3007.
73. FJ Giordano (2005) Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 115 500-508.
74. JM Hare and JS Stamler (2005) NO/redox disequilibrium in the failing heart and cardiovascular system. J Clin Invest 115 509-517.
75. K Hogg, K Swedberg and J McMurray (2004) Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 43 317-327.
76. DA Kass, JG Bronzwaer and WJ Paulus (2004) What mechanisms underlie diastolic dysfunction in heart failure? Circ Res 94 1533-1542.
77. F Kuwahara, H Kai, K Tokuda, M Takeya, A Takeshita, K Egashira, et al. (2004) Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation? Hypertension 43 739-745.
78. KT Weber (2004) From inflammation to fibrosis: a stiff stretch of highway. Hypertension 43 716-719.